Post-earnings recap
Reported
Thu, Nov 2, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss per share of $0.62, but the stock still rose by 3.22% following the earnings report. This increase may reflect investor optimism or reactions to other market factors, as no guidance or detailed commentary was provided during the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, and the analysis is based solely on numerical results.